Author

Emily Tamar Tatoian

Observed name: Emily Tatoian

Institution: Icahn School of Medicine at Mount Sinai

Observed institutions: Stanford Medicine, Stanford University, Icahn School of Medicine at Mount Sinai

OpenAlex ID: A5008468233

Timing of Antihypertensive Medications on Key Outcomes in Hemodialysis: A Cluster Randomized Trial

2021 · Tara I. Chang, Emily Tamar Tatoian, et al. · Kidney360 · 11

Outcomes from the Multicenter ACCRU-LY-1804/CARiBOU (Cytarabine, Acalabrutinib and Rituximab integrated with Bortezomib-based Outpatient therapy) Trial in 1st line Mantle Cell Lymphoma

2025 · Stephen Smith, Suchitra Sundaram, et al. · Blood · 1

Outcomes From the Multicenter ACCRU ‐ LY ‐1804/ CARiBOU TRIAL (Cytarabine, Acalabrutinib and Rituximab Integrated With Bortezomib‐Based Outpatient Therapy) in 1st Line Mantle Cell Lymphoma

2026 · Stephen D. Smith, Suchitra Sundaram, et al. · American Journal of Hematology

Works count: 3

Citation count: 12

H-index: 1

I10-index: 1